Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false and misleading statements regarding its business performance and financial guidance during the Class Period from November 7, 2024, to July 8, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [5]. - Defendants allegedly overstated the demand for RxSight's products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [5]. - The misleading statements made by the defendants about RxSight's business operations and prospects caused investors to suffer damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased RxSight securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by September 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].
ROSEN, LEADING INVESTOR COUNSEL, Encourages RxSight, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RXST